Hans Morreau

Prof. Hans Morreau


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2004 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
AJAndrea E. de Jong
Andrea E. de Jong
MPMarjo van Puijenbroek
Marjo van Puijenbroek
YHYvonne Hendriks
Yvonne Hendriks
CTCarli Tops
Carli Tops
JWJuul Wijnen
Juul Wijnen
HMHans Morreau
Hans Morreau
Purpose: Immunohistochemistry (IHC) and microsatellite instability (MSI) analysis can be used to identify patients with a possible DNA mismatch repair defect [hereditary nonpolyposis colorectal carcinoma (HNPCC)]. The Bethesda criteria have been proposed to select families for determination of MSI. The aims of this study were to assess the yield of MSI analysis in families suspected for HNPCC, to compare the results of immunohistochemical staining and MSI analysis, and to assess the additional value of PMS2 staining. Experimental Design: Clinical data and tumors were collected from 725 individuals from 631 families with suspected HNPCC. MSI analysis was performed using eight markers including the 5 National Cancer Institute markers. Four immunohistochemical staining antibodies were used (MLH1, MSH2, MSH6 and PMS2). Results: A MSI-H (tumors with instability for >30% of the markers) phenotype in colorectal cancers (CRCs) was observed in 21–49% of families that met the various Bethesda criteria. In families with three cases of CRC diagnosed at age > 50 years, families with a solitary case of CRC diagnosed between ages 45 and 50 years, and families with one CRC case and a first-degree relative with a HNPCC-related cancer, one diagnosed between ages 45 and 50 years (all Bethesda-negative families), the yield of MSI-H was 10–26%. Immunohistochemical staining confirmed the MSI results in 93% of the cases. With IHC, adding PMS2 staining led to the identification of an additional 23% of subjects with an hMLH1 germ-line mutation (35 carriers were tested). Conclusions: The Bethesda guidelines for MSI analysis should include families with three or more cases of CRC diagnosed at age > 50 years. The age at diagnosis of CRC in the original guidelines should be raised to 50 years. Routine IHC diagnostics for HNPCC should include PMS2 staining.

9 December 2015 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
AJAnne Ml Jansen
Anne Ml Jansen
TWTom Van Wezel
Tom Van Wezel
BABrendy Ewm van Den Akker
Brendy Ewm van Den Akker
MGMarina Ventayol Garcia
Marina Ventayol Garcia
DRDina Ruano
Dina Ruano
HMHans Morreau
Hans Morreau
Many suspected Lynch Syndrome (sLS) patients who lack mismatch repair (MMR) germline gene variants and MLH1 or MSH2 hypermethylation are currently explained by somatic MMR gene variants or, occasionally, by germline POLE variants. To further investigate unexplained sLS patients, we analyzed leukocyte and tumor DNA of 62 sLS patients using gene panel sequencing including the POLE, POLD1 and MMR genes. Forty tumors showed either one, two or more somatic MMR variants predicted to affect function. Nine sLS tumors showed a likely ultramutated phenotype and were found to carry germline (n=2) or somatic variants (n=7) in the POLE/POLD1 exonuclease domain (EDM). Six of these POLE/POLD1-EDM mutated tumors also carried somatic MMR variants. Our findings suggest that faulty proofreading may result in loss of MMR and thereby in microsatellite instability.

23 March 2017 in JCI Insight
Verified
Journal Article
Open access
PDF file
CPChetanya Pandya
Chetanya Pandya
AUAndrew V. Uzilov
Andrew V. Uzilov
JBJustin Bellizzi
Justin Bellizzi
CLChun Yee Lau
Chun Yee Lau
AMAye S. Moe
Aye S. Moe
RCRong Chen
Rong Chen
Parathyroid carcinoma (PC) is an extremely rare malignancy lacking effective therapeutic intervention. We generated and analyzed whole-exome sequencing data from 17 patients to identify somatic and germline genetic alterations. A panel of selected genes was sequenced in a 7-tumor expansion cohort. We show that 47% (8 of 17) of the tumors harbor somatic mutations in the CDC73 tumor suppressor, with germline inactivating variants in 4 of the 8 patients. The PI3K/AKT/mTOR pathway was altered in 21% of the 24 cases, revealing a major oncogenic pathway in PC. We observed CCND1 amplification in 29% of the 17 patients, and a previously unreported recurrent mutation in putative kinase ADCK1 . We identified the first sporadic PCs with somatic mutations in the Wnt canonical pathway, complementing previously described epigenetic mechanisms mediating Wnt activation. This is the largest genomic sequencing study of PC, and represents major progress toward a full molecular characterization of this rare malignancy to inform improved and individualized treatments.

1 June 2015 in Gastroenterology
Verified
Journal Article
Closed access
Noel de MirandaNoel de Miranda
Noel de Miranda
MDMaarten van Dinther
Maarten van Dinther
BABrendy E.W.M. van Den Akker
Brendy E.W.M. van Den Akker
TWTom van Wezel
Tom van Wezel
PDPeter Ten Dijke
Peter Ten Dijke
HMHans Morreau
Hans Morreau

22 February 2007 in BMC Cancer
Verified
Journal Article
Open access
JDJan Willem F Dierssen
Jan Willem F Dierssen
Noel de MirandaNoel de Miranda
Noel de Miranda
SFSoldano Ferrone
Soldano Ferrone
MPMarjo van Puijenbroek
Marjo van Puijenbroek
CCCees J Cornelisse
Cees J Cornelisse
HMHans Morreau
Hans Morreau
Background: Abnormalities in Human Leukocyte Antigen (HLA) class I expression are common in colorectal cancer. Since HLA expression is required to activate tumor antigen-specific cytotoxic T-lymphocytes (CTL), HLA class I abnormalities represent a mechanism by which tumors circumvent immune surveillance. Tumors with high microsatellite instability (MSI-H) are believed to face strong selective pressure to evade CTL activity since they produce large amounts of immunogenic peptides. Previous studies identified the prevalence of HLA class I alterations in MSI-H tumors. However, those reports did not compare the frequency of alterations between hereditary and sporadic MSI-H tumors neither the mechanisms that led to HLA class I alterations in each subgroup.Methods: To characterize the HLA class I expression among sporadic MSI-H and microsatellite-stable (MSS) tumors, and HNPCC tumors we compared immunohistochemically the expression of HLA class I, β2-microglobulin (β2m), and Antigen Processing Machinery (APM) components in 81 right-sided sporadic and 75 HNPCC tumors. Moreover, we investigated the genetic basis for these changes.Results: HLA class I loss was seen more frequently in MSI-H tumors than in MSS tumors (p < 0.0001). Distinct mechanisms were responsible for HLA class I loss in HNPCC and sporadic MSI-H tumors. Loss of HLA class I expression was associated with β2m loss in HNPCC tumors, but was correlated with APM component defects in sporadic MSI-H tumors (p < 0.0001). In about half of the cases, loss of expression of HLA class I was concordant with the detection of one or more mutations in theβ2mand APM components genes.Conclusion: HLA class I aberrations are found at varying frequencies in different colorectal tumor types and are caused by distinct genetic mechanisms. Chiefly, sporadic and hereditary MSI-H tumors follow different routes toward HLA class I loss of expression supporting the idea that these tumors follow different evolutionary pathways in tumorigenesis. The resulting variation in immune escape mechanisms may have repercussions in tumor progression and behavior.

20 July 2007 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
CHC. J. Haven
C. J. Haven
MPM. Van Puijenbroek
M. Van Puijenbroek
MTM. H. Tan
M. H. Tan
BTBin Tean Teh
Bin Tean Teh
GFG. J. Fleuren
G. J. Fleuren
HMHans Morreau
Hans Morreau